Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

First Posted Date
2023-11-30
Last Posted Date
2024-02-28
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
12
Registration Number
NCT06151847
Locations
🇺🇸

University of Kansas Cancer Center, Kansas City, Kansas, United States

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

First Posted Date
2023-11-30
Last Posted Date
2024-10-16
Lead Sponsor
David Porter
Target Recruit Count
24
Registration Number
NCT06152172
Locations
🇺🇸

Hospital of the Universithy of Pennsylvania, Philadelphia, Pennsylvania, United States

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

First Posted Date
2023-11-21
Last Posted Date
2024-01-03
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
54
Registration Number
NCT06140966
Locations
🇨🇳

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

First Posted Date
2023-11-09
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
680
Registration Number
NCT06124157

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

First Posted Date
2023-11-08
Last Posted Date
2023-11-08
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
24
Registration Number
NCT06121557
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

First Posted Date
2023-11-08
Last Posted Date
2023-11-08
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
24
Registration Number
NCT06121570
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

First Posted Date
2023-11-07
Last Posted Date
2024-10-04
Lead Sponsor
Indapta Therapeutics, INC.
Target Recruit Count
128
Registration Number
NCT06119685
Locations
🇺🇸

Valkyrie Clinical Trials, Los Angeles, California, United States

🇺🇸

Stanford University, Stanford, California, United States

🇺🇸

Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center, Lake Mary, Florida, United States

and more 10 locations

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

First Posted Date
2023-11-01
Last Posted Date
2024-12-19
Lead Sponsor
AstraZeneca
Target Recruit Count
1728
Registration Number
NCT06112379
Locations
🇻🇳

Research Site, Vinh, Vietnam

ATG Plus Low-dose PT-Cy for GVHD Prevention

Phase 3
Recruiting
Conditions
Hematologic Malignancy
Interventions
Drug: Cyclophosphamid
Drug: ATG
First Posted Date
2023-10-31
Last Posted Date
2024-03-21
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
196
Registration Number
NCT06108739
Locations
🇨🇳

Peking University People's Hospital, Beijing, China

HCT With PTCy in Higher-risk MDS

First Posted Date
2023-10-24
Last Posted Date
2023-10-24
Lead Sponsor
Asan Medical Center
Target Recruit Count
113
Registration Number
NCT06098313
Locations
🇰🇷

Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy